New hints towards a precision medicine strategy for IDH wild-type 2 Glioblastoma
Glioblastoma (GBM) represents the most common primary malignancy of the central 56 nervous system in adults, and remains a largely incurable disease. The elucidation 57 of disease subtypes based on mutational profiling, gene expression and DNA 58 methylation has so far failed to translate into improved clinical outcomes. However, Journal Pre-proof 3 59 new knowledge emerging from the subtyping effort in the IDH-wildtype setting may 60 provide directions for future precision therapies. Here, we review recent learnings in 61 the field, and further consider how tumour microenvironment (TME) differences 62 across subtypes may reveal novel contexts of vulnerability. We discuss recent 63 treatment approaches and ongoing trials in the IDH-wildtype GBM setting, and 64 propose an integrated discovery stratagem incorporating multi-omics, single cell 65 technologies and computational approaches.